FAQs
- Why has this change happened?
- How does the new dispensing model work?
- What do I need to do now?
- What happens to Allergan Direct?
- Is the 50-Unit BOTOX (botulinum toxin type A) vial available through this model?
- What is the list price for the 50-Unit vial of BOTOX?
- How must BOTOX (botulinum toxin type A) be supplied under this process?
- How will the JUVÉDERM (hyaluronic acid) range and SKINVIVE by JUVÉDERM (hyaluronic acid injectable gel) be supplied?
- What is the pricing for the JUVÉDERM range and SKINVIVE by JUVÉDERM when supplied as individual syringes?
- Will there be training or support for my team?
- What should I say to my patients?
- How does this differ from the Fresh model that was just launched?
- Will this fulfill any audit requirements Queensland Health may impose?
- Will the new model delay product availability?
- Will APP customers still earn points under the new pharmacy model?
- Does the new pharmacy dispensing model change how points are calculated?
- How will the third-party pharmacy know my APP pricing and status?
- Will my APP benefits or tier status be impacted by this change?
- Is there anything I need to do differently as an APP customer?
- How will the 50-Unit BOTOX (botulinum toxin type A) vial be counted in the APP program?
- Can I process scripts for non-Allergan Aesthetics products via this process?
- What if I have issues with the Chemist2U portal?
- How will I know when to expect my product to arrive?
- How will products be delivered?
- What are the order, delivery, and fee details?
- How will evaluation stock and training product be managed?
- Will Allergan Aesthetics capture any patient details through this process?
- What additional costs will a clinic incur with this dispensing model?